Editorial: risk assessment for chronic hepatitis B patients in the immune tolerant phase-both definition and selection matter
Aliment Pharmacol Ther
.
2020 Jul;52(1):213-214.
doi: 10.1111/apt.15798.
Authors
Yao-Chun Hsu
1
2
,
Yen-Tsung Huang
3
Affiliations
1
Center for Liver Diseases and School of Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
2
Division of Gastroenterology, Fu-Jen Catholic University Hospital, New Taipei, Taiwan.
3
Institute of Statistical Science, Academia Sinica, Taipei, Taiwan.
PMID:
32529769
DOI:
10.1111/apt.15798
No abstract available
Publication types
Editorial
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Carcinoma, Hepatocellular*
Hepatitis B e Antigens
Hepatitis B virus
Hepatitis B, Chronic*
Humans
Liver Neoplasms*
Risk Assessment
Substances
Hepatitis B e Antigens